Takeda Products Ireland Ltd
Unit 2051, Castle Drive
Citywest Business Campus
Dublin 24
News, Articles & Press Releases
24-Jul-2012New treatment for essential hypertension, Edarbi® (azilsartan medoxomil) launches in Ireland
Ireland, 24-Jul-2012 /HealthPRZone.com/- Takeda Products Ireland Ltd,

Azilsartan medoxomil provides significant reductions in blood pressure (BP) that are maintained over 24-hours, including the risky early morning period, when patients are at the highest risk of cardiovascular events such as stroke or heart attacks. 1,2

Takeda Products Ireland Limited would like to announce that Edarbi® (azilsartan medoxomil) is now available for prescription in Ireland. Edarbi® is a new once-daily angiotensin receptor blocker (ARB) indicated for the treatment of essential hypertension.

Hypertension is estimated to affect just under half of the adult population (44%)3 and the majority of patients will require medication to control their blood pressure over the long-term. The launch of azilsartan medoxomil provides an important new treatment option for people who need to optimise their blood pressure control.

Azilsartan medoximil is supported by a wealth of data from seven phase III clinical trials, involving nearly 6,000 patients with hypertension.2 The studies showed that the highest approved dose of azilsartan medoxomil (80mg/day) resulted in significantly greater reductions in mean 24-hour and clinic blood pressure than the highest approved doses of the ARBs olmesartan medoxomil (40mg/day)4,5 and valsartan (320mg/day)4,6 and the ACE inhibitor ramipril (10mg/day).7 In clinical studies, adverse reactions associated with treatment with azilsartan medoxomil were mostly mild or moderate, with an overall incidence similar to placebo.2 The most commonly observed treatment-related adverse reactions are dizziness, increased blood creatine phosphokinase and diarrhoea.2

“The launch of azilsartan medoxomil marks an important milestone for Takeda, building on our 30-year heritage in cardiovascular disease and reinforcing our commitment to expand the boundaries of hypertension treatment, address unmet needs and ultimately optimise patient outcomes across Europe,” said Trevor Smith, CEO, Takeda Pharmaceuticals Europe. “We believe azilsartan medoxomil provides clinicians with a highly effective option for patients with essential hypertension who remain uncontrolled with their current medication.”

Azilsartan medoximil is available in 20mg, 40mg and 80mg doses (all 28 tablet packs). The Summary of Product Characteristics is available at www.medicines.ie.


1. White WB. Importance of aggressive blood pressure lowering when it may matter most. American Journal of Cardiology. 2007; 100:10J-16J
2. Azilsartan medoxomil Summary of Product Characteristics available at www.medicines.ie.
3. Wolf-Maier K, Cooper RS et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. Journal of the American Medical Association. 2003; 289(18):2363-2369
4. White WB, Weber MA, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011; 57(3):413-420
5. Bakris GL, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. The Journal of Clinical Hypertension. 2011; 13(2):81-88
6. Sica D, White WB, Weber MA. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. The Journal of Clinical Hypertension. 2011; 13:467-472
7. Bonner G. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. Abstract. Presented at European Society of Hypertension meeting, 18-21 June 2010, Oslo, Norway
8. Taubman M. Angiotensin II. A Vasoactive Hormone With Ever-Increasing Biological Roles. Circulation Research. 2003; 92:9
9. British Heart Foundation. Blood pressure. Available from: http://www.bhf.org.uk/heart-health/conditions/high-blood-pressure.aspx [Last accessed May 2012]
10. WHO. Global health risks: Mortality and burden of disease attributable to selected major risks. 2009. Available from: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf [Last accessed May 2012]

Date of preparation: May 2012
Job Code: IAZL120401


For further information
Takeda Products Ireland Ltd
Jedd Comiskey

Unit 2051, Castle Drive
Citywest Business Campus
Dublin 24

Email: click to reveal